Table 3.
VAS scores of pain intensity at baseline and at the end of the study.
| Study Groups | VAS Score, Mean ± SD | % Improvement Due to Product | Within-Group p Value |
Between-Group p Value |
|
|---|---|---|---|---|---|
| Baseline | Final (8 Weeks) |
||||
| Placebo (n = 30) | 5.1 ± 1.7 | 4.0 ± 2.2 | - | 0.006 | 0.001 |
| Boswellia (n = 29) | 5.4 ± 1.8 | 2.4 ± 1.8 | 29.6 | 0.001 | |
| AvailOm® (n = 31) | 5.3 ± 1.5 | 2.3 ± 2.2 | 30.7 | 0.001 | |
| Boswellia + AvailOm® (n = 30) | 5.4 ± 1.9 | 2.4 ± 2.0 | 29.6 | 0.001 | |
VAS: visual analog scale; SD: standard deviation, % improvement due to product: percentage of improvement of each product after eliminating the placebo effect of the control group.